https://www.selleckchem.com/pr....oducts/bgb-283-bgb28
bieneusi and the associated risk factors, and advocates the importance of the One Health approach to tackle E. bieneusi infections. Tocilizumab has been proposed as a treatment for the new disease COVID-19, however, there is not enough scientific evidence to support this treatment. The objective of this study is to analyze whether the use of tocilizumab is associated with respiratory improvement and a shorter time to discharge in patients with COVID-19 and lung involvement. Observational study on a cohort of 418 patients, admitte
お気に入り
コメント
シェア
